1. Market Research
  2. > Pharmaceutical Market Trends

China Pharmaceutical Guidebook Series (2) 2013 Edition - Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Chemical Drugs

  • April 2013
  • 121 pages
  • Access China Management Consulting Ltd.
Report ID: 1163525

Summary

Table of Contents

Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which gave a fillip to the imported drugs from overseas pharmaceutical manufacturers and producers. By 2012, sales of imported drugs have shared one fourth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door of a lucrative drug market for overseas pharmaceutical companies. More and more overseas pharmaceutical manufacturers and producers expect to enter such drug market and seize a larger part of such drug market. To enter such a lucrative drug market, the first obstacle faced by overseas pharmaceutical manufacturers and producers is how to file the application for their imported drug registration with Chinese pharmaceutical authorities.

In China, the process of application and approval for imported drug registration is very complex, because the Chinese pharmaceutical authorities administer and control this process by exorbitant administrative measures and regulations, moreover, these exorbitant administrative regulations are variable and lack of transparency. Therefore, a comprehensive and thorough knowledge of the latest Chinese regulations for imported drug registration has been become an essential prerequisite for overseas pharmaceutical manufacturers and producers to achieve a successful application for their products entry into the Chinese drug market. Access China Management Consulting Ltd published the China Pharmaceutical Guidebook Series: 2013 Edition. The aim of this guidebook series is to guide overseas pharmaceutical manufacturers and producers to achieve a successful application and approval for their imported drug registration.

This guidebook series are composed of four guidebooks as the following.

- Latest Chinese Regulations for Imported Drug Registration: 2013 Edition
A Comprehensive Guidebook for Foreign Pharmaceutical Companies

- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: 2013 Edition
A Guidebook for Application of Imported Chemical Drugs Registration

- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: 2013 Edition
A Guidebook for Application of Imported Biological Product Registration

- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: 2013 Edition
A Guidebook for Application of Imported Traditional Chinese Medicine and Natural Medicine Registration

This is the second guidebook of the China Pharmaceutical Guidebook Series. It will provide a detailed introduction of SFDA’s requirements for materials and clinical trials of application and approval for imported chemical drug registration, including radioactive pharmaceuticals.

Chapter 2 provides an overview of the classification of drug registration that is formulated by the SFDA. To understand this classification of drug registration only is the first step for an application of chemical drug registration, because applicant must file the application in accordance with this classification of drug registration. Chapter 3 addresses the material items for application of chemical drug registration. The SFDA collected all materials for application of chemical drug registration into four categories and 32 items. There are the summary materials, the research materials of pharmaceutics, the research materials of pharmacology and toxicology, and the materials of clinical investigation. For administrative requirement of chemical drug registration, the SFDA provides the detailed explanations for many material items and precedes the ordinal numeral for each material item. When an application is filed, the SFDA will request applicant to submit the materials for application of chemical drug registration of various categories in accordance with the material item’s ordinal numeral. Therefore, to understand the material items is the second step for application of chemical drug registration. Chapter 4 introduces the requirements of material items for application of chemical drug registration in terms of the form of material items and their explanatory notes. The form of material items represents the current requirements of material items for application of chemical drug registration stipulated by the SFDA. The explanatory notes further explain the requirements of material items for various categorical chemical drugs.

To understand the contents of this section is a core for application of chemical drug registration. The application of imported chemical drug registration must accord with the material items prescribed by the form of material Items and the explanatory notes to submit materials. Chapter 5 addresses the requirements of clinical trial for application of chemical drug registration. There are two parts, i.e. the general requirements of clinical trial and the special requirements of clinical trial for imported chemical drug. Chapter 6 introduces the material and clinical trial requirements for application of radioactive pharmaceuticals, from the definitions, the requirements of material items, the explanatory notes of material items to the requirements of clinical trial. The guidebook concludes in chapter 7 by highlighting the significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their chemical drug registration in China. Last, the appendices in chapter 8 include the Drug Administration Law of the People’s Republic of China, the Regulations for Implementation of Drug Administration Law of the People’s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Application Form of Imported Drug Registration, references, and description of Access China Management Consulting Ltd. After have skimmed through this guidebook, audience can be clearly aware of the latest Chinese regulations on requirements of the materials and the clinical trials for application of imported chemical drug registration. For the detailed pathway and procedure for application and approval of imported drug registration, audience can learn from the first guidebook of the China Pharmaceutical Guidebook Series (2013 Edition) ---- Latest Chinese Regulations for Imported Drug Registration: A Comprehensive Guidebook for Foreign Pharmaceutical Companies.

Report Highlights

- An overview of the classification of drug registration formulated by the SFDA (The State Food and Drug Administration in China).
- The material items for application of drug registration.
- The requirements of material items for application of drug registration.
- The requirements of clinical trial for application of drug registration.
- The material and clinical trial requirements for application of radioactive pharmaceuticals
- The significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their chemical drug registration in China.
- Many useful resources of law and regulations, including the Drug Administration Law of the People’s Republic of China, the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Form of Registration Application for Imported Drug, and so on.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025 Summary Cystic fibrosis (CF), which has been given a the diagnostic code E84 from The International Classification of Diseases, ...

High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global high-content screening (HCS) market is projected to reach USD 909.0 million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are ...

Pharmaceutical Filtration Market by Product (Membrane Filters, Single-Use Systems), Technique (Microfiltration, Ultrafiltration), Application (Final Product Processing, Raw material), Scale of Operation (Manufacturing, Pilot, R&D) - Global Forecast to 202

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global pharmaceutical filtration market is projected to reach USD 22.71 billion by 2021 from USD 13.73 billion in 2016, at a CAGR of 10.6% from 2016 to 2021. Market growth is primarily driven by factors ...

Social Media In Pharma

March 2017 $ 5000

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.